最新ニュース Lonza Group (OTC:LZAGY) 株価情報

LONZA GROUP AG

Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.

LONZA GROUP AG UNSP/ADR by Lonza Group AG

Lonza Group Ltd

European pharma service provider Lonza Group Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LZAGY#OTC">LZAGY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LZAGF#OTC">LZAGF</a>) announced plans to exit its Capsules &amp; Health Ingredients (CHI) business.
Full implementation is expected by second quarter of 2025.
The decision coincides with the company&#8217;s strategy to focus on contract development and manufacturing organization (CDMO). Lonza expects EBITDA margins exceeding 30% for its CDMO segment beyond 2025.
William Blair writes that the decision to divest its CHI business and reorganize the CDMO business &#8220;rids Lonza of the main drag&#8221; and &#8220;creates a much cleaner and more compelling pure-play CDMO story.&#8221;
The new structure aims to simplify operations by transitioning from three divisions and nine business units to three integrated business platforms: Integrated Biologics, Advanced Synthesis, and Specialized Modalities.
The Integrated Biologics platform will consolidate Mammalian and Drug Product Services, while Advanced Synthesis merges hybrid chemistry and biology solutions, incorporating the Small Molecules division and Bioconjugates.
Specialized Modalities will be focused on cell and gene therapies, mRNA, and microbial solutions.
2024 and Beyond: Growth Outlook
<ul>
<li>Lonza maintained its 2024 guidance of flat constant exchange rate (CER) sales growth and a CORE EBITDA margin between 27% and 29%, with CDMO performance offsetting softness in the CHI segment.</li>
<li>For 2025, Lonza projects CER sales growth approaching 20%, supported by the acquisition of the Vacaville site and organic growth in the low teens.</li>
<li>Beyond 2025, the company anticipates low-teen percentage CER sales growth.</li>
<li>For CHI, Lonza expects modest growth and a gradual return to higher margins post-2025.</li>
<li>Lonza reaffirmed its commitment to a dividend policy with a payout ratio of 35-45%.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42465586/gevo-and-lg-chem-push-ahead-on-eto-commercialization-for-sustainable-aviation-and-bio-propylene-markets" target="_blank" rel="noreferrer noopener">Gevo And LG Chem Double Down On Ethanol-To-Olefins Tech: Details</a></li>
</ul>

Analyst Color

News

Health Care

Analyst Ratings

General

LZAGF

LZAGY

Swiss Contract Service Provider Lonza Exits Capsules Business To Focus On Drug Development

Wednesday,&nbsp;Roche Holding AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>)&nbsp;<a target="_blank" href="https://assets.roche.com/f/176343/x/24b7c8339b/20032024_ms_vacavillelonza.pdf" rel="noreferrer noopener">entered</a>&nbsp;into a definitive agreement with Lonza Group Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LZAGF#OTC">LZAGF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LZAGY#OTC">LZAGY</a>).
Under the agreement, Lonza will acquire the Genentech manufacturing facility in Vacaville, California, for $1.2 billion in conjunction with a manufacturing agreement and related quality services and warehousing.&nbsp;
Under the terms of the agreement, Lonza will offer approximately 750 Genentech employees at the Vacaville facility employment, and the products currently produced at the site by Roche will continue to be supplied by Lonza for a transition period.&nbsp;
The&nbsp;<a target="_blank" href="https://www.lonza.com/news/2024-03-20-07-00" rel="noreferrer noopener">acquisition</a>&nbsp;will increase Lonza's large-scale biologics manufacturing capacity. The Vacaville (US) facility currently has a total bioreactor capacity of around 330,000 liters, making it one of the largest biologics manufacturing sites in the world by volume.&nbsp;
Lonza plans to invest approximately CHF 500 million in additional Capex to upgrade the Vacaville (US) facility and enhance capabilities to satisfy demand for the next generation of mammalian biologics therapies.&nbsp;
The products currently manufactured at the site by Roche will be supplied by Lonza, with committed volumes over the medium term, phasing out over time as the site transitions to serve alternative customers.
As the transaction is expected to be accretive to sales growth, Lonza has updated its mid-term guidance for 2024–2028.&nbsp;
Its sales growth range was set at 11–13% CAGR in CER and has now been updated to 12 – 15%.&nbsp;
Mid-term guidance for core EBITDA margin and ROIC remains unchanged.&nbsp;
The transaction is expected to close by H2 2024.

Biotech

RHHBY

Swiss Healthcare Manufacturing Firm Lonza Bolsters Biologics Manufacturing Capacity With Roche's US Facility Acquisition For $1.2B

<ul>
<li>Galapagos&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/glpg#NASDAQ">GLPG</a>)&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/22/06/g27802064/galapagos-to-acquire-cellpoint-and-aboundbio-to-accelerate-access-to-next-generation-cell-therapie" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">agreed to acquire</a>&nbsp;CellPoint and AboundBio in an all-cash transaction propelling into next-generation cell therapy while significantly broadening its portfolio and capabilities.</li>
<li>Galapagos will pay an upfront amount of &euro;125 million for CellPoint, an additional &euro;100 million to be paid upon achieving certain milestones, and $14 million for AboundBio.&nbsp;</li>
<li>Galapagos said that, through the acquisition of CellPoint and AboundBio, it gains access to an automated point-of-care cell therapy supply model and a next-generation fully human antibody-based therapeutics platform.</li>
<li>Related:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/22/05/27086970/rbc-expects-business-development-to-unlock-this-pharma-stocks-balance-sheet-value" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">RBC Expects Business Development To Unlock This Pharma Stock&#39;s Balance Sheet Value</a>.</li>
<li>The deal aims for three next-generation CAR-Ts to the clinic over the next three years.</li>
<li>CellPoint has developed a novel point-of-care supply model, which offers the potential for efficient, 7-day delivery of CAR-T therapies and avoids complex logistics.&nbsp;</li>
<li>The proprietary platform consists of CellPoint&#39;s end-to-end xCellit workflow management and monitoring software and&nbsp;Lonza Group&#39;s (OTC: <a class="ticker" href="https://www.benzinga.com/stock/lzagf#OTC">LZAGF</a>) Cocoon system, a closed, automated manufacturing platform for cell and gene therapies.</li>
<li>Price Action:&nbsp;GLPG shares are down 1.91% at $54.93 during the premarket session on the last check Wednesday.</li>
</ul>

GLPG

Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field

<ul>
<li>Moderna Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) is gearing up to halve the dose of its COVID-19 vaccine so that it can also be used to combat variants and inoculate children.</li>
<li>It&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/06/b21382536/moderna-announces-new-drug-substance-production-agreement-with-lonza-in-the-netherlands" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">has entered into a deal&nbsp;</a>with&nbsp;Lonza Group&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/lzagf#OTC">LZAGF</a>) for a new drug substance production line in Geleen, Netherlands, which will have the capacity to make ingredients for up to 300 million doses annually at 50 micrograms per dose.</li>
<li>The new agreement with Lonza will increase drug substance production in Europe by the fourth quarter of 2021.</li>
<li>Currently, Moderna has been delivering an approved 100-microgram dose to date.</li>
<li>It said early booster shot data for a 50-microgram version&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/21/04/20615391/modernas-covid-19-shot-provides-over-90-effectiveness-six-months-after-second-dose-boosters-can-p" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">showed it helped protect against emerging virus variants</a>.</li>
<li>Combined with a previous deal with Spain&#39;s Rovi, Moderna&#39;s pact with Lonza brings 50-microgram production in Europe to up to 600 million doses annually, with the capacity due to come online in 2021.</li>
<li>Price Action:&nbsp;MRNA shares closed at $184.66 on Tuesday.</li>
</ul>

Contracts

MRNA

Moderna, Lonza Team Up To Produce New Drug Substance for COVID-19 Vaccine Doses

<ul>
<li>Moderna Inc&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/mrna#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">MRNA</a>) plans to&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/04/b20854594/moderna-announces-additional-investments-to-increase-global-supply-for-covid-19-vaccine-to-up-to-3" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">produce up to 3 billion doses in 2022</a>, doubling capacity at contract sites in Switzerland and Spain run by&nbsp;Lonza Group&nbsp;(OTCMKTS: LZAGF) and&nbsp;Rovi, respectively, and increasing drug substance manufacturing by 50% at its U.S. facilities.</li>
<li>The expansions will also allow Moderna to now produce between 800 million and 1 billion doses in 2021, the company said.</li>
<li>The actual number of doses will depend on the manufacturing split between 100-microgram vaccine doses and potentially lower-dose boosters and pediatric vaccines, the company said.</li>
<li>The financial terms of the expansion were not disclosed, but Moderna said it is funding the move out of pocket.</li>
<li>The increases announced today are in addition to the recently announced increases in formulation, fill and finish in the U.S. with&nbsp;Catalent Inc&nbsp;(NYSE:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/ctlt#NYSE" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">CTLT</a>) and&nbsp;Sanofi S.A.&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/sny#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">SNY</a>).</li>
<li>Sanofi entered an agreement earlier this week to&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/21/04/20788258/sanofi-steps-in-for-fill-finish-200m-doses-of-modernas-covid-19-vaccine" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">help manufacture 200 million doses</a>&nbsp;of Moderna&rsquo;s COVID-19 vaccine at its Ridgefield, NJ site. That will begin in September.</li>
<li>CDMO Catalent announced that it was&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/04/b20499456/moderna-and-catalent-announce-long-term-strategic-collaboration-for-dedicated-vial-filling-of-mode" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">upping the production capacity</a>&nbsp;of the vaccine in its Bloomington, IN biologics facility through its new high-speed vial filling line. Those doses are expected to be ready in May.</li>
<li>Additionally, citing new data, Moderna says the COVID-19 vaccine can remain stable at temperatures found in refrigerators for three months.</li>
<li>Currently, the mRNA vaccine is approved to be stored in the refrigerator between 2-8&deg;C for up to 30 days and up to seven months in the freezer at -20&deg;C.&nbsp;</li>
<li>Price Action: MRNA shares are up 1.85% at $181.98 in the premarket trading on the last check Thursday.</li>
</ul>

CTLT

Moderna Tries To Boost COVID-19 Vaccine Supply Chain To Produce 3B Doses Annually

<ul>
<li>aTyr Pharma Inc&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/life#NASDAQ" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">LIFE</a>) and&nbsp;Lonza Group Ltd&nbsp;(OTCMKTS: LZAGF) have&nbsp;<a class="editor-rtfLink" href="http://benzinga.com/pressreleases/21/04/g20616957/atyr-pharma-and-lonza-announce-manufacturing-agreement-for-atyrs-anti-nrp2-antibody-atyr2810" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">agreed to manufacture</a>&nbsp;ATYR2810, aTyr&#39;s monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical development for cancer.</li>
<li>Under the terms of the agreement, Lonza will utilize its Ibex Design to manufacture material for ATYR2810.</li>
<li>The deal will cover the early stages from gene to Investigational New Drug. It will provide both drug substance and drug product to support toxicological studies in animals and early clinical development in humans.</li>
<li>The scope will include process support, including cell line development, process development, and supply chain simplification, to drug substance &amp; product manufacturing at Lonza&#39;s Visp and Stein sites in Switzerland.</li>
<li>ATYR2810 is a fully-humanized monoclonal antibody designed to specifically and functionally block the interaction between NRP2 and one of its primary ligands, VEGF.</li>
<li>Price Action:&nbsp;LIFE shares are up 1.9% at $3.81 on the last check Wednesday.</li>
</ul>

Penny Stocks

LIFE

aTyr Pharma Recruits Lonza As Manufacturing Partner For Cancer Therapy ATYR2810

Altimmune Inc&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/alt#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">ALT</a>)&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/21/03/g20136315/altimmune-expands-adcovid-manufacturing-collaboration-with-lonza" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">has expanded</a>&nbsp;its&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/20/11/g18290282/altimmune-adds-lonza-as-a-manufacturing-partner-for-supply-of-adcovid-its-single-dose-intranasal-v" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">previously-announced</a>&nbsp;manufacturing collaboration with&nbsp;Lonza Group&nbsp;(OTCMKT: LZAGY) for AdCOVID, its single-dose intranasal COVID-19 vaccine candidate.
<ul>
<li>Under the expansion, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, at its facility near Houston, Texas.&nbsp;&nbsp;</li>
<li>In December, the&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/20/12/g18916880/altimmune-provides-an-update-on-its-investigational-new-drug-application-for-a-phase-1-adcovid-cli" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">FDA issued a clinical hold</a>&nbsp;on Altimmune&#39;s investigational New Drug application for AdCOVID. The agency requested certain protocol modifications and the submission of additional chemistry, manufacturing, and controls data.&nbsp;</li>
<li>The recently&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/general/biotech/21/02/19702134/altimmunes-adcovid-vaccine-gets-positive-fda-update" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">commenced Phase 1 study</a>&nbsp;with data readout is expected in the second quarter of 2021.</li>
<li>Price Action:&nbsp;ALT shares gained 19.7% at $20.20 in the premarket trading on the last check Friday.</li>
</ul>

Small Cap

Altimmune Shares Are Trading Higher On Expanded Manufacturing Pact With Lonza

Upgrades

Downgrades

Initiation

Intraday Update

ADDYY

AGFY

DISH

DMYD

FLOW

GLOG

GTES

HEINY

HMPT

ICPT

INTU

LPTH

OKTA

ONEW

PANW

PING

REAL

SBUX

SMFKY

SNSS

SPWR

TECH

TLTZY

TMST

UWMC

VRTX

Benzinga's Top Ratings Upgrades, Downgrades For February 23, 2021

JP Morgan analyst Richard Vosser upgrades Lonza Group (OTC:<a class="ticker" href="/stock/LZAGY#OTC">LZAGY</a>) from Neutral to Overweight.

JP Morgan Upgrades Lonza Group to Overweight

KeyBanc initiates coverage on Lonza Group (OTC:<a class="ticker" href="/stock/LZAGY#OTC">LZAGY</a>) with a Sector Weight rating.

KeyBanc Initiates Coverage On Lonza Group with Sector Weight Rating

Moderna Inc.&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) <a href="https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-expansion-barda-agreement-support-larger-phase">announced</a> Sunday&nbsp;it is receiving another $472 million funding from President Donald Trump&#39;s administration to&nbsp;support late-stage clinical development of its coronavirus vaccine candidate, including an expanded phase 3 study.
<h3>What Happened</h3>
The Cambridge, Massachusetts-based company was originally allocated a $483 million award, in support of its mRNA-1273 vaccine candidate, as part of its contract with the Biomedical Advanced Research and Development Authority (BARDA). Now that amount is being ratcheted up to $955 million as Moderna expects to conduct phase 3 trials with a significantly higher number of participants.
The biotechnology firm revealed that its phase 3 study, to be conducted in collaboration with the Anthony Fauci-led National Institute of Allergy and Infectious Diseases, is expected to begin Monday. The trial would include 30,000 participants in the United States.
<h3>Why It Matters</h3>
Moderna claims it&#39;s on track to deliver nearly 500 million doses of the vaccine per year, and it could scale that number up to 1 billion doses&nbsp;next year&nbsp;due to its strategic collaboration with Lonza Group AG (OTC: <a class="ticker" href="https://www.benzinga.com/stock/lzagy#OTC">LZAGY</a>).
The company said it is also collaborating with Catalent Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ctlt#NYSE">CTLT</a>) for fill-finish manufacturing of the vaccine at that company&rsquo;s Indiana facility.&nbsp;
Last week, Moderna <a href="https://www.benzinga.com/general/biotech/20/07/16763338/moderna-faces-hurdle-with-coronavirus-vaccine-as-court-refuses-to-invalidate-arbutus-patent">suffered</a> a setback in its vaccine development as it lost a bid to invalidate a key patent related to the technology for delivery of mRNA vaccines held by Arbutus Biopharma Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abus#NASDAQ">ABUS</a>).
The U.S. government is upping investments in the development, testing and production of the COVID-19 treatment.&nbsp;Earlier this month, it promised&nbsp;$1.6 billion in funding to Novavax, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvax#NASDAQ">NVAX</a>) for its vaccine&rsquo;s late-stage trial, <a href="https://www.politico.com/news/2020/07/26/trump-invests-moderna-vaccine-candidate-381690">reported</a> Politico.&nbsp;
&ldquo;We&rsquo;re very close to the vaccine &mdash; I think we&rsquo;re going to have some very good results,&rdquo; Trump reportedly said Tuesday.
<h3>Price Action</h3>
Moderna shares closed 2.8% lower at $73.21 on Friday and traded about 1.1% higher in the after-hours session.

Government

Financing

Media

ABUS

NVAX

Moderna Gets Another $472M Federal Funding For Late-Stage Coronavirus Vaccine Development

Comments

Lonza Group

ニュース

最新ニュース Lonza Group (OTC:LZAGY) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル